Apoptosis induced FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases

被引:47
|
作者
Mitsiades, N
Poulaki, V
Mitsiades, CS
Koutras, DA
Chrousos, GR
机构
[1] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA USA
[3] Univ Athens, Sch Med, GR-11527 Athens, Greece
[4] NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA
来源
关键词
D O I
10.1016/S1043-2760(01)00441-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
FasL and TRAIL/Apo2L participate in cell-mediated cytotoxicity by inducing apoptosis in susceptible cells via respective cell surface receptors. Normal and neoplastic thyroid tissues are resistant-to FasL-induced apoptosis but are sensitized by Th-1-type cytokines. In Hashimoto's thyroiditis, both FasL and its receptor, Fas, are strongly upregulated and their interaction leads to the suicidal/fratricidal death of thyrocytes. In Graves' disease, FasL expression in thyroid follicular cells is induced by thionamides and kills infiltrating lymphocytes. In this condition, Th-2-type cytokines upregulate the anti-apoptotic molecules FLIP and Bcl-x(L) and protect thyrocytes from apoptosis. FasL is expressed by neoplastic thyrocytes and induces apoptosis of infiltrating lymphocytes. TRAIL/Apo2L kills thyroid carcinoma cells but spares normal thyrocytes,thus providing a potential therapy for thyroid cancer.
引用
收藏
页码:384 / 390
页数:7
相关论文
共 50 条
  • [1] Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
    Holland, Pamela M.
    CANCER LETTERS, 2013, 332 (02) : 156 - 162
  • [2] Targeting apoptosis in cancer with Apo2L/TRAIL
    Ashkenazi, A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 3 - 3
  • [3] The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis
    Mace, Thomas A.
    Yamane, Nariyuke
    Cheng, Jinrong
    Hylander, Bonnie L.
    Repasky, Elizabeth A.
    IMMUNOLOGICAL INVESTIGATIONS, 2006, 35 (3-4) : 279 - 296
  • [4] New insights into apoptosis signaling by Apo2L/TRAIL
    Gonzalvez, F.
    Ashkenazi, A.
    ONCOGENE, 2010, 29 (34) : 4752 - 4765
  • [5] New insights into apoptosis signaling by Apo2L/TRAIL
    F Gonzalvez
    A Ashkenazi
    Oncogene, 2010, 29 : 4752 - 4765
  • [6] Cellular pathways mediating APO2L/TRAIL-induced apoptosis in glioma cells
    Rieger, J
    Weller, M
    Frank, B
    Wick, W
    NEURO-ONCOLOGY, 2005, 7 (03) : 317 - 317
  • [7] Apo2L/TRAIL and immune regulation
    Anel, Alberto
    Bosque, Alberto
    Naval, Javier
    Pineiro, Andres
    Larrad, Luis
    Angeles Alava, Maria
    Jose Martinez-Lorenzo, Maria
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 : 2074 - 2084
  • [8] Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis
    Balsas, Patricia
    Lopez-Royuela, Nuria
    Galan-Malo, Patricia
    Anel, Alberto
    Marzo, Isabel
    Naval, Javier
    BIOCHEMICAL PHARMACOLOGY, 2009, 77 (05) : 804 - 812
  • [9] Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer
    Martinez-Lostao, Luis
    Marzo, Isabel
    Anel, Alberto
    Naval, Javier
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (11) : 1475 - 1483
  • [10] Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
    Almasan, A
    Ashkenazi, A
    CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (3-4) : 337 - 348